Ascendis Will Take On Daily Genotropin With Weekly Skytrofa
Company Will Try To Assert Superiority Claim
Ascendis’s growth hormone deficiency drug Skytrofa will offer a convenience advantage as a weekly injectable. But the label does not clearly delineate superiority shown in a Phase III trial.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: StrataGraft Continues US FDA’s Biologic Center Approvals Streak; Another CRL For Avenue’s Tramadol IV
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The latest transaction in Pfizer's year-end dealmaking flurry gives the company an exclusive global license for Opko Health's once-weekly human growth hormone (hGH) candidate Lagova (hGH-CTP), which complements the big pharma's once-daily growth hormone Genotropin (somatropin).